Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

Blood Adv. 2022 Sep 13;6(17):5124-5127. doi: 10.1182/bloodadvances.2022007708.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Proto-Oncogene Proteins c-bcl-2
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use

Substances

  • BCL2 protein, human
  • Proto-Oncogene Proteins c-bcl-2
  • Pyrimidines
  • Agammaglobulinaemia Tyrosine Kinase